SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: DMore who wrote (9262)5/9/1998 3:24:00 AM
From: milton  Respond to of 14328
 
dmore:
I received the triby 97 annual report today. Page 28 lists the self shares at 12/97 as $1.978 million (cost). The footnote lists the stock at market as $6.9098 million (12/31/97). Final sentence in the same footnote states:
"The Company has obtained counsels' advice relating to this investment and the Directors of the Company are satisfied that the group has valid legal title."
Go triby!
PS: A little distressed at the recent hostilities on this thread. Better energy is spent on tracking down hard info and sharing it than lobbing insults. Let's see some more technical data or the quality comments like those from Keiko.



To: DMore who wrote (9262)5/11/1998 10:02:00 AM
From: Steve Stuart  Respond to of 14328
 
If the SLF shares are carried as trading securities, they must be carried at market value, with charges/gains as the share price fluctuates. It sounds more reasonable to label them as investment securities, however, in which case I think they would be carried at cost until sold. You're right that earnings will be less volatile if the shares are carried at cost.

-Steve Stuart


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News